ImmunoGen, Inc. (IMGN)

NASDAQ: IMGN · IEX Real-Time Price · USD
5.31
+0.04 (0.76%)
At close: Aug 10, 2022 4:00 PM
5.16
-0.15 (-2.82%)
After-hours: Aug 10, 2022 5:48 PM EDT

Company Description

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer.

The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.

Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

ImmunoGen, Inc.
ImmunoGen Logo
Country United States
Founded 1980
IPO Date Nov 16, 1989
Industry Biotechnology
Sector Health Care
Employees 106
CEO Mark Enyedy

Contact Details

Address:
84 State St
Boston, Massachusetts 02109-2202
United States
Phone 781 895 0600
Website immunogen.com

Stock Details

Ticker Symbol IMGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0000855654
CUSIP Number 45253H101
ISIN Number US45253H1014
Employer ID 04-2726691
SIC Code 2834

Key Executives

Name Position
Mark Joseph Enyedy President, Chief Executive Officer and Director
Susan Altschuller Ph.D. Senior Vice President and Chief Financial Officer
Dr. Anna Berkenblit M.D., MM.Sc Senior Vice President and Chief Medical Officer
Stacy A. Coen Senior Vice President and Chief Business Officer
Kristen Harrington-Smith Senior Vice President and Chief Commercial Officer
Renee Lentini Vice President of Finance and Principal Accounting Officer
Courtney O'Konek Senior Director of Corporate Communications and Investor Relations
Joseph J. Kenny Vice President, Acting General Counsel, Intellectual Property and Secretary
Audrey Bergan Senior Vice President and Chief Human Resources Officer
Dr. Theresa G. Wingrove Senior Vice President of Regulatory Affairs and Quality

Latest SEC Filings

Date Type Title
Aug 1, 2022 S-8 Securities to be offered to employees in employee benefit plans
Aug 1, 2022 S-8 Securities to be offered to employees in employee benefit plans
Aug 1, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
Jul 29, 2022 8-K Current report
Jul 5, 2022 4 Statement of changes in beneficial ownership of securities
Jul 5, 2022 4 Statement of changes in beneficial ownership of securities
Jul 5, 2022 4 Statement of changes in beneficial ownership of securities
Jul 5, 2022 4 Statement of changes in beneficial ownership of securities
Jul 5, 2022 4 Statement of changes in beneficial ownership of securities
Jul 5, 2022 4 Statement of changes in beneficial ownership of securities